Sign Up to like & get recommendations! 1
Published in 2022 at "Neuropsychopharmacology Reports"
DOI: 10.1002/npr2.12244
Abstract: Supporting patients upon discharge following prolonged hospitalization in private psychiatric hospitals in Japan have long been an issue. This study evaluated the efficacy of clozapine in treating long‐stay patients with treatment‐resistant schizophrenia to reduce the… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Journal of Autism and Developmental Disorders"
DOI: 10.1007/s10803-018-3589-7
Abstract: There is paucity of empirical data regarding the use of either clozapine or electroconvulsive therapy (ECT) in the acute phase and maintenance treatment of schizophrenia in adults with intellectual disability. Herein we report the successful… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Brain Stimulation"
DOI: 10.1016/j.brs.2020.08.008
Abstract: Approximately 60% of patients with treatment-resistant schizophrenia (TRS) do not respond to a trial of clozapine [1]. This is termed clozapine-resistant schizophrenia (CRS). A recent metanalysis showed that clozapine augmentation with ECT is efficacious for… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "European Psychiatry"
DOI: 10.1016/j.eurpsy.2017.01.1639
Abstract: Introduction Treatment resistance to clozapine is estimated at 40–70% of the treated population. Several clozapine potentiation strategies have come into clinical practice although often without evidence-based support. Objective The aim of our work was to… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Journal of psychiatric research"
DOI: 10.1016/j.jpsychires.2018.08.002
Abstract: Treatment-resistant schizophrenia (TRS) is common and debilitating. A subgroup of patients even has clozapine-resistant schizophrenia (CRS). We aimed to evaluate the efficacy and safety of electroconvulsive therapy (ECT) augmentation of clozapine for CRS. Systematic literature… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Journal of psychiatric research"
DOI: 10.1016/j.jpsychires.2021.03.053
Abstract: Treatment-resistant schizophrenia (TRS) has a quite complex pathophysiology that includes not only severe positive symptoms but also other symptom domains. Much attention has been devoted to the overlapping psychological and biological profiles of schizophrenia and… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Neurobiology of Disease"
DOI: 10.1016/j.nbd.2018.08.016
Abstract: Treatment resistant schizophrenia (TRS) refers to the significant proportion of schizophrenia patients who continue to have symptoms and poor outcomes despite treatment. While many definitions of TRS include failure of two different antipsychotics as a… read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "Psychiatry Research"
DOI: 10.1016/j.psychres.2020.113698
Abstract: Clozapine is the only evidence-based drug indicated for Treatment Resistant Schizophrenia but it is largely underprescribed, partially due to its life-threatening adverse effects (AEs). However, clozapine treatment is burdened by other common AEs as constipation,… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Schizophrenia Research"
DOI: 10.1016/j.schres.2016.10.012
Abstract: Schizophrenia is a chronic psychiatric disorder with complex genetic and environmental origins. While many antipsychotics have been demonstrated as effective in the treatment of schizophrenia, a substantial number of schizophrenia patients are partially or fully… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Schizophrenia Research"
DOI: 10.1016/j.schres.2020.01.002
Abstract: Early identification of symptoms that can predict treatment-resistant schizophrenia (TRS) could help clinicians to avoid delays in clozapine therapy. This study aims to investigate symptom patterns that could predict TRS using a discovery/replication study design.… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Molecular Psychiatry"
DOI: 10.1038/s41380-022-01572-0
Abstract: Antipsychotic drugs are the mainstay in the treatment of schizophrenia. However, one-third of patients do not show adequate improvement in positive symptoms with non-clozapine antipsychotics. Additionally, approximately half of them show poor response to clozapine,… read more here.